A clinical trial investigating the effect of the FXR agonist INT-747 in patients with type 2 diabetes and non-alcoholic fatty liver disease, concluded that FXR activation improved insulin sensitivity and reduced markers of liver inflammation and fibrosis [61]. This evidence concerns the gene INS and metabolic dysfunction-associated steatotic liver disease.